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Introduction: The primary objectives of this phase I study were 
to evaluate the safety and maximum tolerated dose (MTD) of 
SAR245409, a pan-class I phosphatidylinositol 3-kinase (PI3K)/
mammalian target of rapamycin inhibitor, combined with erlotinib in 
patients with advanced solid tumors.
Methods: Forty-six patients with advanced solid tumors were enrolled. 
Patients with lung cancer (n = 37) had received an epidermal growth 
factor receptor (EGFR) inhibitor before study entry. SAR245409 30, 
50, 70, or 90 mg once daily (QD) or 20 or 30 mg twice daily (BID) was 
administered, in combination with erlotinib 100 mg QD, in 28-day 
cycles. Dose escalation of SAR245409 followed a standard 3 + 3 
design. Patients were evaluated for adverse events (AEs). Additional 
evaluations included pharmacokinetics, pharmacodynamic effects on 
PI3K and EGFR/mitogen-activated protein kinase signaling pathways 
in tumor and skin samples, and tumor response.
Results: The MTDs of SAR245409, in combination with erlotinib 
100 mg QD, were 70 mg QD and 20 mg BID. The most frequently 
reported treatment-related AEs (any grade) were diarrhea (35%), 
rash (35%), and nausea (28%). No treatment-related AE occurred 
at grade 3/4 in more than one patient (2.2%). No major pharmaco-
kinetic interaction between SAR245409 and erlotinib was noted. 
Suppression of PI3K and EGFR/mitogen-activated protein kinase 
signaling pathway biomarkers was observed in skin and tumor sam-
ples. Stable disease was the best overall response reported, occurring 
in 12 of 32 (37.5%) evaluable patients.
Conclusion: MTDs of SAR245409 and erlotinib were below the 
single-agent doses of either agent, despite the lack of major pharma-
cokinetic interaction.
Key Words: PI3K/mammalian target of rapamycin inhibitor, 
Epidermal growth factor receptor inhibitor, Pharmacokinetics, 
Pharmacodynamics, Advanced solid tumors.
(J Thorac Oncol. 2014;9: 316–323)
The phosphatidylinositol 3-kinase (PI3K) signaling path-way plays an important role in essential cellular functions, 
including growth, cell survival, and metabolism.1,2 Aberrant 
PI3K signaling is implicated in tumor cell invasion, migration, 
and dissemination.3 Molecular alterations that dysregulate the 
PI3K signaling pathway, such as deletion or downregulation of 
phosphatase and tensin homolog (PTEN) or somatic mutations 
in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic 
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subunit alpha (PIK3CA), occur frequently in multiple tumor 
types, including breast, colon, and endometrial cancers and 
glioblastoma.4,5 Hyperactivation of the PI3K signaling pathway 
is associated with resistance to anticancer therapies, including 
resistance of epidermal growth factor receptor (EGFR)-mutant 
non–small-cell lung cancer (NSCLC) to EGFR tyrosine kinase 
inhibitors (TKIs) and mediated by mechanisms such as insulin-
like growth factor 1 receptor activation and increased MET sig-
naling.6–8 In a preclinical study, exogenous activation of PI3K 
signaling was sufficient to render EGFR inhibitor–sensitive 
EGFR mutant cells resistant to gefitinib.9 Furthermore, another 
study found that an acquired PIK3CA mutation was present in 
samples from one of 37 patients with erlotinib-resistant EGFR-
mutant NSCLC.10 Consistent with these observations, PI3K 
pathway inhibition has been shown to sensitize cancer cells to 
various agents, including EGFR inhibitors.8,11–16
SAR245409 (XL765) is a pan-class I PI3K/mammalian 
target of rapamycin (mTOR) inhibitor with specific adenos-
ine triphosphate (ATP)-competitive reversible binding to the 
catalytic domains of PI3K and mTOR.17–19 Preclinical stud-
ies showed that SAR245409 inhibited PI3K/mTOR signaling, 
significantly slowing tumor growth or shrinking tumors in 
multiple models; these antitumor effects correlated with inhi-
bition of tumor cell proliferation and angiogenesis and induc-
tion of apoptosis.17
Prompted by these findings, we performed a phase 
I study (TED11442/XL765-003) investigating treatment 
with SAR245409 combined with erlotinib in patients with 
advanced solid tumors, including patients with lung cancer 
previously treated with EGFR TKIs.
PATIENTS AND METHODS
Patients
Patients aged 18 years or older with Eastern Cooperative 
Oncology Group performance status 1 or less, acceptable 
organ function, and a histologically or cytologically confirmed 
solid tumor that was metastatic or unresectable and was no 
longer responding to therapies or for which no standard treat-
ment exists were eligible. Patients with lung cancer must have 
received an EGFR inhibitor before study entry. Patients who 
were intolerant to erlotinib or who had received previous treat-
ment with a PI3K inhibitor were not eligible. For any previous 
treatment, the last dose must have been administered at least 3 
weeks before the first dose of SAR245409.
Study Design and Treatment
This was a phase I, open-label, nonrandomized study. 
Dose escalation of SAR245409 followed a standard 3 + 3 
design. Doses administered to different patient cohorts in 
28-day cycles were 30, 50, 70, or 90 mg once daily (QD) and 
20 or 30 mg twice daily (BID). SAR245409 was taken con-
comitantly with erlotinib 100 mg QD after a 2-week  run-in 
period during which single-agent erlotinib was adminis-
tered. A starting dose of 100 mg of erlotinib was chosen 
because of the potential overlap in adverse events (AEs) with 
SAR245409. Primary study objectives were to evaluate the 
safety and maximum tolerated dose (MTD) of SAR245409 
when combined with erlotinib. Secondary objectives were to 
evaluate the pharmacokinetics (PK) and preliminary efficacy 
of the treatment regimen. Pharmacodynamic effects were 
evaluated as exploratory objectives. The total patient num-
ber was not predetermined and depended on the number of 
dose cohorts and patients required to establish an MTD. The 
study was registered at ClinicalTrials.gov (NCT00777699). 
Approval was obtained from ethics committees of participat-
ing institutions and regulatory authorities. All patients pro-
vided informed consent. The study followed the Declaration 
of Helsinki and Good Clinical Practice guidelines.
Safety
Safety was evaluated using standard clinical and labo-
ratory assessments and through monitoring of AEs (NCI 
CTCAE version 3.0)20 and Eastern Cooperative Oncology 
Group performance status. All AEs occurring during treat-
ment or within 30 days of last treatment dose were recorded. 
Dose-limiting toxicity (DLT) was defined as the occurrence of 
a specified event during cycle 1 that warranted a dose reduc-
tion or, that in the opinion of the Cohort Review Committee, 
was of potential clinical significance such that further dose 
escalation would expose patients to unacceptable risk (includ-
ing gastrointestinal AEs, hyperglycemia, hematologic AEs, 
and liver enzyme elevations; a full definition is provided in 
Supplemental Digital Content 1, Supplementary Methods, 
http://links.lww.com/JTO/A521).
PK Evaluations
Plasma concentrations of SAR245409 and erlotinib 
were assayed using liquid chromatography tandem mass spec-
trometry. The following PK parameters were determined: C
max
 
(maximum plasma concentration observed), t
max
 (time to reach 
C
max
), AUC
0–12
 or AUC
0–24
 (area under the plasma concentra-
tion versus time curve from 0 to 12 or 0 to 24 hours postdose), 
and t
1/2z
 (terminal half-life associated with the terminal slope). 
Further details are provided in Supplemental Digital Content 
1, Supplementary Methods (http://links.lww.com/JTO/A521).
Pharmacodynamic and Molecular 
Profiling Evaluations
Pharmacodynamic evaluations were conducted to 
determine the level of PI3K and EGFR pathway inhibition 
and included the phosphorylation state of signaling proteins 
(AKT, 4E-binding protein 1 [4EBP1], EGFR, and extracel-
lular signal-regulated kinase [ERK] 1/2) in skin and tumor 
tissue. Molecular profiling evaluations were performed to 
investigate the molecular basis of acquired resistance to EGFR 
TKIs and included the assessment of mutations and/or copy 
number variation within genes of interest (including EGFR, 
PIK3CA, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homo-
log [KRAS], MET, liver kinase B1 [LKB1], and various other 
PI3K pathway components/modulators). Tissue sampling was 
optional during the dose escalation phase. Noninvasive sam-
ples were collected from some subjects, but due to technical 
challenges with these sample types, they were not analyzed. 
Full details of the pharmacodynamic methods are provided 
318 Copyright © 2014 by the International Association for the Study of Lung Cancer
Jänne et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 3, March 2014
in Supplemental Digital Content 1, Supplementary Methods 
(http://links.lww.com/JTO/A521).
Efficacy Assessments
Tumor response was assessed using Response Evaluation 
Criteria In Solid Tumors v1.0.21 Patients were evaluated every 
8 weeks during SAR245409 treatment until disease progres-
sion or discontinuation. Partial response or complete response 
had to be confirmed 4 weeks after initial achievement. For sta-
ble disease (SD), criteria had to be met for 6 weeks. Disease 
progression was defined per Response Evaluation Criteria In 
Solid Tumors or by clinical deterioration.
RESULTS
Patients
Between October 2008 and March 2011, 46 patients 
were enrolled: 33 in the QD group and 13 in the BID group 
(Table 1). All patients had received a prior anticancer treat-
ment; 26 (56.5%) patients had received more than two 
prior anticancer regimens, and 50% (n = 23) had received 
both anticancer drugs and radiation. All patients with lung 
cancer (n = 37, 80.4%) had received a prior EGFR inhibi-
tor, of which 25 had received erlotinib as part of their last 
treatment regimen before study entry. Four patients (all QD 
group) discontinued during the erlotinib run-in period and 
did not receive SAR245409. The median duration (range) 
of treatment with SAR245409 and erlotinib was 56 (0–346) 
and 70 (9–360) days, respectively. All patients discontin-
ued study treatment; the most common reasons were disease 
progression (34 patients; 73.9%), AEs (4 patients; 8.7%), 
and withdrawal of consent (4 patients; 8.7%), and propor-
tions were similar between treatment groups defined by dos-
ing levels/schedules.
DLT and MTD
Four patients experienced DLTs (2 of 5 patients in the 
90 mg QD group and 2 of 6 patients in the 30 mg BID group). 
These included grade 2 photophobia (90 mg QD) in a patient 
with a prior dose interruption for photophobia, grade 3 sto-
matitis (90 mg QD), grade 3 generalized rash (30 mg BID), 
and grade 4 cerebrovascular accident (30 mg BID), which 
occurred 3 days after treatment had been discontinued fol-
lowing the discovery of brain metastases. MTDs were deter-
mined to be SAR245409 70 mg QD plus erlotinib 100 mg 
QD and SAR245409 20 mg BID plus erlotinib 100 mg QD. 
An expansion cohort was planned (per protocol) but not initi-
ated because of both apparent lack of efficacy and because 
the MTDs in both cohorts were below the recommended 
phase II dose of SAR245409 (90 mg QD or 50 mg BID) and 
below the registered dose of erlotinib (150 mg QD, which was 
not tested).
Safety
The most frequently reported AEs (any grade), regard-
less of causality, were diarrhea (28 patients; 60.9%), rash (21 
patients; 45.7%), nausea (20 patients; 43.5%), and vomiting 
(15 patients; 32.6%) (Table, Supplemental Digital Content 
2, http://links.lww.com/JTO/A522; AEs occurring in ≥10% 
of patients). Except for rash, which was more common with 
SAR245409 30 mg QD than with other dosing regimens, there 
were no dose-related trends. Twenty patients (43.5%) experi-
enced a grade 3/4 AE; the most frequently reported, regardless 
of causality, were dyspnea (5 patients; 10.9%) and vomiting 
(4 patients; 8.7%). Although grade 3/4 AEs were more com-
mon with BID versus QD treatment, there were no notable 
dose-related trends in AEs. AEs considered related or possibly 
related to treatment occurred in 41 patients (89.1%; Table 2); 
no consistent dose-related trends were observed. Four patients 
TABLE 1.  Patient Demographics and Baseline Characteristics
SAR245409 Dose Cohort
30 mg QD  
(n = 6)
50 mg QD  
(n = 12)
70 mg QD  
(n = 10)
90 mg QD  
(n = 5)
20 mg BID  
(n = 7)
30 mg BID  
(n = 6)
Total  
(N = 46)
Age in yrs, median (range) 59.5 (38–71) 62.5 (49–76) 60.0 (55–67) 61.0 (52–75) 63.0 (39–77) 56.5 (47–77) 60.0 (38–77)
Sex, n (%)
  Male 2 (33.3) 3 (25.0) 5 (50.0) 2 (40.0) 2 (28.6) 3 (50.0) 17 (37.0)
  Female 4 (66.7) 9 (75.0) 5 (50.0) 3 (60.0) 5 (71.4) 3 (50.0) 29 (63.0)
ECOG PS, n (%)
  0 1 (16.7) 5 (41.7) 7 (70.0) 2 (40.0) 2 (28.6) 2 (33.3) 19 (41.3)
  1 5 (83.3) 7 (58.3) 3 (30.0) 3 (60.0) 5 (71.4) 4 (66.7) 27 (58.7)
Primary tumor site
  Lung 4 (66.7) 10 (83.3) 10 (100) 4 (80.0) 5 (71.4) 4 (66.7) 37 (80.4)
  Colon 0 1 (8.3) 0 0 1 (14.3) 1 (16.7) 3 (6.5)
  Cervix 0 0 0 0 1 (14.3) 0 1 (2.2)
  Liver 0 0 0 0 0 1 (16.7) 1 (2.2)
  Other 2 (33.3) 1 (8.3) 1 (8.3) 1 (20.0) 0 0 4 (8.7)
Metastatic disease yes/no 5/1 12/0 10/0 5/0 7/0 5/1 44/2
BID, twice daily; ECOG PS, Eastern Cooperative Oncology Group performance status; QD, once daily.
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experienced a treatment-related serious AE: grade 3 DRESS 
(drug reaction [or rash] with eosinophilia and systemic symp-
toms) syndrome (70 mg QD; n = 1), which led to treatment 
discontinuation; grade 2 photophobia (DLT; 90 mg QD; n = 1) 
and grade 2 nausea and vomiting (20 mg BID; n = 1), which 
led to dose interruption; and grade 4 cerebrovascular accident 
(DLT; 30 mg BID; n = 1). Four patients (8.7%) had an AE 
that led to discontinuation of study treatment. In addition, one 
patient discontinued during the erlotinib run-in period because 
of AEs. Two patients had treatment-related AEs, leading to 
study drug discontinuation during treatment with SAR245409 
and erlotinib (the patient with grade 3 DRESS and the patient 
with grade 2 increases in aspartate aminotransferase and ala-
nine aminotransferase).
PK Analysis
With QD treatment, SAR245409 exposure on day 
22 increased over the three-fold dose range (30–90 mg) in 
a greater than dose-proportional manner (mean C
max
 and 
AUC
0–24
 increased by 5.54- and 4.66-fold, respectively) 
(Table 3). With BID dosing, the increased exposure on 
day 22 to SAR245409 20 to 30 mg was dose proportional 
(C
max
 and AUC
0–12
 increased by 1.46- and 1.30-fold, respec-
tively). After SAR245409 administration (30–90 mg QD and 
20–30 mg BID) with erlotinib (100 mg), SAR245409 was 
absorbed with a median t
max
 ranging from 1.6 to 2.0 hours, 
and mean t
1/2
 for the QD group ranged from 4.30 to 8.03 
hours (t
1/2
 was not calculated for the BID group). In differ-
ent SAR245409 dose cohorts, the median t
max
 for erlotinib 
ranged from 1.5 to 6.8 hours (Table 3). After 36 days of erlo-
tinib dosing (day −14 to 22), mean accumulation ratios for 
C
max
 and AUC
0–24
 ranged from 1.29 to 3.76 and 1.86 to 4.09, 
respectively. No major PK interaction between SAR245409 
and erlotinib was noted (Figure, Supplemental Digital 
Content 3, http://links.lww.com/JTO/A524; erlotinib plasma 
concentration–time profiles).
Pharmacodynamic Analysis
Serial normal skin biopsies from three patients showed 
good antigen preservation and were suitable for analysis by 
immunofluorescence. Of the three patients, two had lung 
adenocarcinoma and one had lung squamous cell carcinoma; 
SAR245409 doses administered were 30, 50, and 50 mg QD, 
respectively. Suppression of PI3K and  EGFR/mitogen-acti-
vated protein kinase (MAPK) pathway biomarkers increased 
over time (pAKTT308: 40%–73%; p4EBP1T70: 43%–67%; pEG-
FRY1045: 31%–62%; and pERKT202/Y204: 37%–75%) (Table 4, 
Fig. 1, and see Supplemental Figure 2, Supplemental Digital 
Content 4, http://links.lww.com/JTO/A523; reduction of PI3K 
and EGFR/MAPK pathway signaling in serial skin samples). 
The maximum inhibition in skin tissue for any PI3K or EGFR/
MAPK biomarker plateaued at approximately 60%–75%.
In one patient with NSCLC adenocarcinoma who had 
prestudy and on-study tumor biopsies available, phospho-
protein biomarkers decreased substantially by cycle 1 day 
21, including biomarkers of the PI3K (pAKTT308 by 57%, 
p4EBP1T70 by 60%) and MAPK (pERKT202/Y204 by 61%) 
pathways (see Supplemental Figure 3, Supplemental Digital 
Content 5, http://links.lww.com/JTO/A537; reduction of PI3K 
and EGFR/MAPK pathway signaling in paired tumor biopsies 
from a patient with NSCLC adenocarcinoma). Furthermore, 
cellular proliferation was reduced by 36%, and apoptosis was 
increased by 1.6-fold. There was a reduction in both pEG-
FRY1045 and total EGFR, making interpretation of effects on 
EGFR difficult. In this patient, a greater pharmacodynamic 
effect was seen in tumor tissue compared with normal tissue 
TABLE 2.  AEs Related to Study Treatment Occurring in ≥5% of Patients
SAR245409 Dose Cohort, n (%)
30 mg QD  
(n = 6)
50 mg QD  
(n = 12)
70 mg QD  
(n = 10)
90 mg QD  
(n = 5)
20 mg BID  
(n = 7)
30 mg BID  
(n = 6)
Total  
(N = 46)
Gr 1/2 Gr ≥3 Gr 1/2 Gr ≥3 Gr 1/2 Gr ≥3 Gr 1/2 Gr ≥3 Gr 1/2 Gr ≥3 Gr 1/2 Gr ≥3 Gr 1/2 Gr ≥3
Any treatment-related AE 6 (100) 0 10 (83) 1 (8) 8 (80) 2 (20) 2 (40) 1 (20) 6 (86) 0 2 (33) 3 (50) 34 (74) 7 (15)
  Diarrhea 2 (33) 0 7 (58) 0 4 (40) 0 0 0 2 (29) 0 1 (17) 0 16 (35) 0
  Rash 5 (83) 0 4 (33) 0 3 (30) 0 2 (40) 0 1 (14) 0 1 (17) 0 16 (35) 0
  Nausea 2 (33) 0 4 (33) 1 (8) 1 (10) 0 1 (20) 0 3 (43) 0 1 (17) 0 12 (26) 1 (2)
  Vomiting 1 (17) 0 2 (17) 1 (8) 1 (10) 0 0 0 2 (29) 0 1 (17) 0 7 (15) 1 (2)
  Fatigue 0 0 2 (17) 0 2 (20) 0 1 (20) 0 2 (29) 0 0 0 7 (15) 0
  Elevated AST 0 0 1 (8) 1 (8) 2 (20) 0 0 0 1 (14) 0 0 0 4 (9) 1 (2)
  Asthenia 0 0 2 (17) 0 2 (20) 0 0 0 0 0 0 0 4 (9) 0
  Dermatitis acneiform 0 0 2 (17) 0 1 (10) 0 0 0 1 (14) 0 0 0 4 (9) 0
  Dry skin 0 0 3 (25) 0 1 (10) 0 0 0 0 0 0 0 4 (9) 0
  Elevated ALT 0 0 1 (8) 0 2 (20) 0 0 0 1 (14) 0 0 0 4 (9) 0
  Cataract 0 0 0 0 1 (10) 0 1 (20) 0 0 0 1 (17) 0 3 (7) 0
  Decreased appetite 0 0 1 (8) 1 (8) 0 0 0 0 1 (14) 0 0 0 2 (4) 1 (2)
  Photophobia 0 0 1 (8) 0 1 (10) 0 1 (20) 0 0 0 0 0 3 (7) 0
AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BID, twice daily; Gr, grade; QD, once daily.
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(pAKTT308, p4EBP1T70, and pERKT202/Y204 were reduced by 
37%–43% in skin). This patient died as a result of disease pro-
gression within 30 days of last dose of study treatment (dura-
tion of treatment was 42 days).
In the patient with lung squamous cell carcinoma who 
had prestudy and on-study tumor biopsies available, pAKTT308 
and pERKT202/Y204 were reduced at cycle 1 day 18 by 67% and 
62%, respectively, and apoptosis was increased (by 2.6-fold). 
In contrast, treatment had only a modest effect on p4EBP1T70, 
with no effect on pEGFRY1173 and no evident inhibition of pro-
liferation (Table 4). This patient died as a result of disease 
progression within 30 days of last dose of study treatment 
(duration of treatment was 59 days).
Molecular Profiling Analyses
Of the 39 patients who received SAR245409 and pro-
vided samples for molecular profiling, 31 had NSCLC. Full 
details of samples with identified mutations are described in 
Supplemental Digital Content 6 (http://links.lww.com/JTO/
A525), Molecular Profiling Analyses. Briefly, molecular alter-
ations were identified in PI3K pathway components; gene copy 
number analyses showed a two- to six-fold amplification of 
PIK3CA in three of eight samples tested (including 1 NSCLC 
patient whose tumor also harbored an activating EGFR muta-
tion), and PTEN alterations were identified in four samples, 
including two with NSCLC. One NSCLC tumor showed a 
lower than expected level of PTEN expression (H-score = 36) 
as assessed by immunohistochemistry. Overall, samples from 
six patients, including three with NSCLC, showed molecular 
alterations in the PI3K/AKT pathway.
Mutations in EGFR were identified in 15 of 27 (55.6%) 
samples from NSCLC patients (none in other tumor types), 
including 11 samples with known activating mutations (such 
as L858R and in-frame deletions in exon 19). Mutations or 
deletions/insertions with unknown function were found in 
three samples. A known mutation associated with de novo 
or acquired resistance to erlotinib (D761Y) was identified 
in one NSCLC patient, along with other EGFR mutations 
of unknown function. A two- to seven-fold amplification of 
EGFR was identified in four of eight samples tested (includ-
ing two NSCLC patients, both of whom also had activating 
EGFR mutations).
Mutations in KRAS were identified in two NSCLC sam-
ples, revealing molecular alterations in the MAPK pathway. 
Mutations in NRAS, TP53, or LKB1 were identified in three 
of 39 patients (1 mutation per patient, all NSCLC except for 
NRAS mutation). None of the four tested NSCLC samples 
exhibited MET copy number variation.
Efficacy
Of the 32 patients with measurable disease who were 
assessed for efficacy at baseline and on study, SD was the 
best overall response reported and occurred in 12 patients 
(37.5%), including 11 patients with NSCLC. Of note, one 
patient with an EGFR mutation had a long duration of treat-
ment (360 days), which corresponded to a long duration of SD 
(11.8 months). The 10 patients with NSCLC who had SD and 
provided samples for molecular analysis included six patients TA
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TABLE 4.  Reduction in Phosphatidylinositol 3-Kinase and EGFR/Mitogen-Activated Protein Kinase Pathway Signaling in Skin 
and Tumor Tissues
Percentage Decrease Relative to Baseline
Serial skin biopsies
Patient Dose, mg  
(SAR245409/ 
erlotinib)
On-study  
sampling day
pAKTT308 p4EBP1T70 pERKT202/Y204 pEGFRY1045 Total EGFR pEGFRY1045/total EGFR
1 30 QD/100 C1D22, predose 40 43 37 44 12 ns 38
2 50 QD/100 C1D22, 4 hr postdose 50 44 44 39 12 ns 31
C3D1, 4 hr postdose 70 64 62 62 12 ns 56
C4D1, predose 73 67 75 65 13 ns 61
3 50 QD/100 C1D22, 4 hr postdose 49 46 47 42 ns 6 ns 38 ns
C3D1, 4 hr postdose 65 55 57 62 15 ns 55
C4D1, postdose 72 57 73 69 16 ns 62
Serial tumor biopsies
Patient Dose, mg  
(SAR245409/ 
erlotinib)
On-study  
sampling day
pAKTT308 p4EBP1T70 pERKT202/Y204 pEGFRY1045 Total EGFR pEGFRY1045/total EGFR Ki67 Tunel  
(fold 
change)
1 30 QD/100 C1D21, 4 hr postdose 57 60 61 38 ns 36 0.4 ns 36 +1.6
4 20 BID/100 C1D18, 4 hr postdose 67 12 ns 62 0.3 nsa — — −9 ns +2.6
C2D1, predose 74 35 3 ns 6.6 nsa — — −197 −4.4
apEGFRY1173.
AKT, serine/threonine-specific protein kinase; BID, twice daily; C, cycle; D, day; EGFR, epidermal growth factor receptor; 4EBP1, 4E-binding protein 1; ERK, extracellular signal-
regulated kinase; ns, not significant; QD, once daily.
FIGURE 1.  Reduction of PI3K and 
EGFR/MAPK pathway signaling by 
SAR245409, in combination with 
erlotinib, in serial skin samples. Effect 
of SAR245409, in combination with 
erlotinib, on the PI3K and EGFR/MAPK 
signaling pathways documented by 
immunofluorescence staining of skin 
biopsies. Quantification at baseline 
(during screening period) and 4 hours 
postdose (on cycle 1, day 22 and cycles 
3 and 4, day 1) of individual patient 
data for pAKTT308, p4EBP1T70, pEG-
FRY1045, total EGFR, and pERKT202/Y204 in 
skin biopsies for three patients admin-
istered erlotinib at 100 mg once daily 
(QD) and SAR245409 at either 30 mg 
QD (n = 1) or 50 mg QD (n = 2). Each 
line represents an individual patient. 
AKT, serine/threonine-specific pro-
tein kinase; C, cycle; D, Day; 4EBP1, 
4E-binding protein 1; ERK, extracel-
lular signal–regulated kinase; PI3K, 
 phosphatidylinositol-3-kinase; EGFR, epi-
dermal growth factor receptor; MAPK, 
mitogen-activated protein kinase.
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with molecular alterations in the EGFR or MAPK pathways; 
none had alterations in the PI3K pathway (Fig. 2). The patient 
with NSCLC with concomitant PI3KCA amplification and 
EGFR-activating mutation did not have SD.
DISCUSSION
Despite the clinical efficacy of EGFR kinase inhibitors 
in patients with EGFR-mutant NSCLC, all patients ultimately 
develop acquired drug resistance. Molecular and biochemical 
analyses from drug-resistant cancers reveal diverse mecha-
nisms of resistance, usually leading to reactivation of EGFR 
and/or downstream signaling pathways.9,10 One such pathway 
is the PI3K/AKT signaling pathway.
In the current study, we evaluated the feasibility of 
whether a pan-PI3K/mTOR inhibitor (SAR245409) could 
be combined clinically with erlotinib and whether this 
combination could lead to reversal of clinical drug resis-
tance in patients with EGFR-mutant, erlotinib-resistant 
NSCLC. Unfortunately, despite two different schedules, the 
MTDs of SAR245409 and erlotinib in combination were 
below the  single-agent doses for both agents (SAR245409-
recommended phase II dose 90 mg QD or 50 mg BID and 
erlotinib-registered dose 150 mg QD), despite no major PK 
interactions between SAR245409 and erlotinib. In addition, 
this combination had limited efficacy at the tolerated dose 
combination. A prior study combining a specific mTOR 
inhibitor, everolimus, with EGFR inhibitors also demon-
strated no objective responses in patients who had developed 
acquired resistance to EGFR inhibitors.22
Twenty-five patients with lung cancer had received an 
erlotinib-based regimen as their last treatment before study 
entry. Two of these patients discontinued during the erlotinib 
run-in period, and 23 patients went on to receive SAR245409 
plus erlotinib. Of these, six (26%) patients received 
SAR245409 plus erlotinib for more than 90 days, with doc-
umented SD at their first disease evaluation. Although this 
could represent potential clinical activity of the combination, 
the lack of objective tumor responses or a control arm pre-
vents making definitive conclusions.
The on-study skin and tumor biopsies provide some 
insight into the lack of clinical efficacy of this therapeutic 
combination. In the limited number of paired specimens, the 
maximum inhibition of PI3K, EGFR, and MAPK (ERK 1/2) 
signaling pathways was between 37% and 75% (Table 4). 
It is not known what degree of inhibition of these path-
ways in tumors is necessary to obtain a clinical response. In 
FIGURE 2.  Waterfall plot of best 
percentage change in tumor size 
(radiologic response) with correspond-
ing status of EGFR, PIK3CA, PTEN, and 
KRAS alterations. Blue indicates gene 
alteration or altered protein expres-
sion, yellow indicates no alteration, 
and gray indicates status unknown. 
Best percentage change from base-
line in the sum of the longest target 
lesions diameter for 30 patients with 
pre- and postbaseline tumor assess-
ments. Dashed lines indicate Response 
Evaluation Criteria In Solid Tumors 
threshold for response (−30% for 
partial response and +20% for pro-
gressive disease). The 10 patients with 
non–small-cell lung cancer who had 
stable disease and provided samples for 
molecular analysis included six patients 
with molecular alterations in the EGFR 
(activating mutations in four patients) 
or mitogen-activated protein kinase 
pathways, and none had alterations 
in the  phosphatidylinositol-3-kinase 
pathway. MTD, maximum tolerated 
dose; QD, once daily; BID, twice daily; 
EGFR, epidermal growth factor receptor; 
PTEN, phosphatase and tensin homo-
log; KRAS, v-Ki-ras2 Kirsten rat sarcoma 
viral oncogene homolog; PTEN, phos-
phatase and tensin homolog; PIK3CA, 
 phosphatidylinositol-4,5-bisphosphate 
3-kinase catalytic subunit alpha.
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 BRAF-mutant melanoma, inhibition of pERK1/2 by more 
than 80% in tumors of patients treated with vemurafenib was 
closely correlated with clinical response.23 Thus, alternative 
dosing strategies with SAR245409, such as intermittent dos-
ing at higher doses, may be necessary to achieve plasma levels 
sufficient to inhibit PI3K signaling to a greater extent than 
achievable in the current daily dosing study.
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